Literature DB >> 29599087

A novel method for strict intranasal delivery of non-replicating RSV vaccines in cotton rats and non-human primates.

Michael P Citron1, Manishkumar Patel2, Mona Purcell2, Shu-An Lin2, Daniel J Rubins2, Paul McQuade2, Cheryl Callahan3, Alexa Gleason2, Ioan Petrescu4, Walter Knapp4, Chinedu Orekie5, Sai Chamarthy5, Zhiyun Wen3, Sinoeun Touch3, Matthew Pine3, Jane Fontenot6, Cameron Douglas3, Xiaoping Liang3, Amy S Espeseth3.   

Abstract

Respiratory syncytial virus (RSV) is the most common viral cause of bronchiolitis and pneumonia in children twelve months of age or younger and a significant cause of lower respiratory disease in older adults. As various clinical and preclinical candidates advance, cotton rats (Sigmodon hispidus) and non-human primates (NHP) continue to play a valuable role in RSV vaccine development, since both animals are semi-permissive to human RSV (HRSV). However, appropriate utilization of the models is critical to avoid mis-interpretation of the preclinical findings. Using a multimodality imaging approach; a fluorescence based optical imaging technique for the cotton rat and a nuclear medicine based positron emission tomography (PET) imaging technique for monkeys, we demonstrate that many common practices for intranasal immunization in both species result in inoculum delivery to the lower respiratory tract, which can result in poor translation of outcomes from the preclinical to the clinical setting. Using these technologies we define a method to limit the distribution of intranasally administered vaccines solely to the upper airway of each species, which includes volume restrictions in combination with injectable anesthesia. We show using our newly defined methods for strict intranasal immunization that these methods impact the immune responses and efficacy observed when compared to vaccination methods resulting in distribution to both the upper and lower respiratory tracts. These data emphasize the importance of well-characterized immunization methods in the preclinical assessment of intranasally delivered vaccine candidates.
Copyright © 2018 Merck Sharp & Dohme Corp and The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Animal models; Cotton rat and non-human primate; Intranasal immunization; Respiratory syncytial virus; Vaccine

Mesh:

Substances:

Year:  2018        PMID: 29599087     DOI: 10.1016/j.vaccine.2018.02.110

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

1.  Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection.

Authors:  Amy S Espeseth; Pedro J Cejas; Michael P Citron; Dai Wang; Daniel J DiStefano; Cheryl Callahan; Gregory O' Donnell; Jennifer D Galli; Ryan Swoyer; Sinoeun Touch; Zhiyun Wen; Joseph Antonello; Lan Zhang; Jessica A Flynn; Kara S Cox; Daniel C Freed; Kalpit A Vora; Kapil Bahl; Andrew H Latham; Jeffrey S Smith; Marian E Gindy; Giuseppe Ciaramella; Daria Hazuda; Christine A Shaw; Andrew J Bett
Journal:  NPJ Vaccines       Date:  2020-02-14       Impact factor: 7.344

2.  Coexpression of respiratory syncytial virus (RSV) fusion (F) protein and attachment glycoprotein (G) in a vesicular stomatitis virus (VSV) vector system provides synergistic effects against RSV infection in a cotton rat model.

Authors:  Kelsey A Brakel; Basavaraj Binjawadagi; Kristen French-Kim; Mauria Watts; Olivia Harder; Yuanmei Ma; Jianrong Li; Stefan Niewiesk
Journal:  Vaccine       Date:  2021-10-23       Impact factor: 3.641

Review 3.  Different Methods and Formulations of Drugs and Vaccines for Nasal Administration.

Authors:  Junhu Tai; Munsoo Han; Dabin Lee; Il-Ho Park; Sang Hag Lee; Tae Hoon Kim
Journal:  Pharmaceutics       Date:  2022-05-17       Impact factor: 6.525

4.  A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults.

Authors:  Antonios O Aliprantis; Christine A Shaw; Paul Griffin; Nicholas Farinola; Radha A Railkar; Xin Cao; Wen Liu; Jeffrey R Sachs; Christine J Swenson; Heather Lee; Kara S Cox; Daniel S Spellman; Colleen J Winstead; Igor Smolenov; Eseng Lai; Tal Zaks; Amy S Espeseth; Lori Panther
Journal:  Hum Vaccin Immunother       Date:  2020-10-29       Impact factor: 3.452

5.  Vaccine containing G protein fragment and recombinant baculovirus expressing M2 protein induces protective immunity to respiratory syncytial virus.

Authors:  Yeong-Min Jo; Jungwoo Kim; Jun Chang
Journal:  Clin Exp Vaccine Res       Date:  2019-01-31

Review 6.  Comparative models for human nasal infections and immunity.

Authors:  Elisa Casadei; Irene Salinas
Journal:  Dev Comp Immunol       Date:  2018-12-01       Impact factor: 3.636

7.  Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection.

Authors:  Amy S Espeseth; Pedro J Cejas; Michael P Citron; Dai Wang; Daniel J DiStefano; Cheryl Callahan; Gregory O' Donnell; Jennifer D Galli; Ryan Swoyer; Sinoeun Touch; Zhiyun Wen; Joseph Antonello; Lan Zhang; Jessica A Flynn; Kara S Cox; Daniel C Freed; Kalpit A Vora; Kapil Bahl; Andrew H Latham; Jeffrey S Smith; Marian E Gindy; Giuseppe Ciaramella; Daria Hazuda; Christine A Shaw; Andrew J Bett
Journal:  NPJ Vaccines       Date:  2020-02-14       Impact factor: 7.344

Review 8.  Factors Limiting the Translatability of Rodent Model-Based Intranasal Vaccine Research to Humans.

Authors:  Lucy Cai; Haiyue Xu; Zhengrong Cui
Journal:  AAPS PharmSciTech       Date:  2022-07-12       Impact factor: 4.026

9.  Volume-Associated Clinical and Histopathological Effects of Intranasal Instillation in Syrian Hamsters: Considerations for Infection and Therapeutic Studies.

Authors:  Catalina Forero; Jana M Ritter; Josilene Nascimento Seixas; JoAnn D Coleman-McCray; Marie Brake; Jillian A Condrey; Cassandra Tansey; Stephen R Welch; Sarah C Genzer; Jessica R Spengler
Journal:  Pathogens       Date:  2022-08-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.